Investor AB CEO Johan Forssell to Step Down in May
By Dominic Chopping
STOCKHOLM--Investor AB Chief Executive Johan Forssell will step down from his position in conjunction with the annual general meeting on May 7, the company said Friday.
Through a consultancy agreement, Forssell will transition to a new role that will see him assigned to Investor as an industrial advisor with a focus on industrial companies, working with board assignments and also working in close collaboration with Investor's business teams.
Forssell has spent nearly 30 years at Investor, with close to nine years as CEO. He is currently a director at Atlas Copco, Epiroc, Wartsila and EQT and will also be engaged by Wallenberg Investments as an industrial advisor.
The Investor board will now begin the recruitment process for his successor, it said.
Investor is the investment vehicle of Sweden's prominent Wallenberg family.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
October 20, 2023 02:46 ET (06:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track